Clinical Trial Update: Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating house dust mite allergen extracts for sublingual immunotherapy in allergic rhinitis. Current status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• House dust mite allergen extracts for sublingual immunotherapy

Snippet

Sponsor: Roxall Medizin | Conditions: Allergic Rhinitis | Phase 3 | Status: UNKNOWN